Open Label Phase III Duloxetine Study for Stress Urinary Incontinence

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Boehringer Ingelheim
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Female out patients

• Are ambulatory and are able to use a toilet independently and without difficulty.

Exclusion Criteria:

• Use of monoamine oxidase inhibitors (MAOIs)